HPE Stock Declines Amid Insider Sale Despite Citigroup Upgrade
What happened
Antonio Neri, CEO of Hewlett Packard Enterprise, sold 250,000 shares of the company on October 5th, totaling $17,077,500.00, under a pre-arranged trading plan. On October 8th, Hewlett Packard Enterprise stock fell 1.6% mid-day trading after the insider sale. Separately, Citigroup raised its target price for Hewlett Packard Enterprise from $76.00 to $92.00 and assigned a "buy" rating.
From dailypolitical.com
Why it matters
The insider sale represented a 17.45% decrease in Antonio Neri's ownership of Hewlett Packard Enterprise stock. This action occurred while Citigroup maintained a positive outlook on the company, setting a high target price. The combination of insider selling and analyst rating changes influenced the stock's trading activity.
From dailypolitical.com
Who's involved
- Hewlett Packard EnterpriseAmerican information technology company whose stock was traded
- Antonio NeriPresident and CEO of Hewlett Packard Enterprise
- CitigroupAmerican investment bank that upgraded the stock rating
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Hewlett Packard EnterpriseSpeculative
Hewlett Packard Enterprise's market price could experience volatility due to the combination of insider selling and analyst rating changes.
Keep exploring
The entities involved
-
Hewlett Packard Enterprise
American information technology company
-
Antonio Neri
Business executive who currently serves as president and chief executive officer of Hewlett Packard Enterprise (1967-)
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup raised its price target and gave a buy rating for Karman Holdings Inc.
- Citigroup raised its price target and gave a buy rating for International Paper, with MarketBeat providing consensus data.
- Citigroup upgraded its target price and gave a buy rating for Fortrea.
- Citigroup provided an analyst rating on SIGHT SCIENCES, INC. stock, and the company disclosed executive stock sales via a legal filing.
- Anixa Biosciences disclosed an insider purchase via SEC filing, coinciding with MarketBeat price target changes and a buy rating restatement from Citigroup.